Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.

[1]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Julia K Mader,et al.  Adipose tissue, inflammation and cardiovascular disease. , 2010, Revista da Associacao Medica Brasileira.

[3]  H. Brenner,et al.  Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. , 2009, European heart journal.

[4]  Rongwei Fu,et al.  Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.

[5]  C. Bouchard,et al.  Body composition, cardiorespiratory fitness, and low-grade inflammation in middle-aged men and women. , 2009, The American journal of cardiology.

[6]  A. Zwinderman,et al.  Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study , 2009, Heart.

[7]  P. Ridker.  Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) , 2009, Journal of thrombosis and haemostasis : JTH.

[8]  H. Brenner,et al.  Association between type II secretory phospholipase A 2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease , 2009 .

[9]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[10]  R. McPherson,et al.  Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. , 2008, Clinical therapeutics.

[11]  N. Paynter,et al.  C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men , 2008, Circulation.

[12]  J. Sundström,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes , 2008 .

[13]  U. Singh,et al.  Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. , 2008, The American journal of cardiology.

[14]  M. Trip,et al.  Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. , 2008, Atherosclerosis.

[15]  Peter Libby,et al.  Inflammation in Atherosclerosis : From Vascular Biology to Biomarker Discovery and Risk Prediction , 2007 .

[16]  J. Danesh,et al.  Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. , 2007, European heart journal.

[17]  Philipp E. Scherer,et al.  Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans , 2007, Diabetes.

[18]  D. Rader.  Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. , 2007, The American journal of medicine.

[19]  R. Peters,et al.  C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. , 2006, Atherosclerosis.

[20]  Amy Shui,et al.  Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.

[21]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[22]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[23]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[24]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[25]  Samy Suissa,et al.  The nested case-control study in cardiology. , 2003, American heart journal.

[26]  T. Mueller,et al.  Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. , 2003, Clinical chemistry.